Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
Sponsor: MiNK Therapeutics
Summary
This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).
Official title: Phase 2 Adaptive Randomized, Placebo -Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-05-26
Completion Date
2027-08
Last Updated
2026-06-26
Healthy Volunteers
No
Conditions
Interventions
agenT-797
Intravenous infusion
Placebo
Intravenous infusion
Standard of Care (SOC)
Antimicrobial therapy and corticosteroids per applicable guidelines.
Locations (4)
UCSF Medical Center at Parnassus Heights
San Francisco, California, United States
Children's Memorial Hermann Hospital
Houston, Texas, United States
University Hospital
San Antonio, Texas, United States
First Lviv Territorial Medical Union
Lviv, Ukraine